Abstract | BACKGROUND: METHODS: A retrospective chart review between July 2021 and January 2023 of 127 consecutive patients who underwent TSA was performed at a tertiary academic institution. Patients were divided into 2 groups based on preoperative aprepitant use. Two groups were matched based on known risk factors of PONV (age, sex, nonsmoking, and history of PONV). The primary outcome was the incidence of PONV. Secondary outcome measures included the number of anti-emetic use, length of stay, and postoperative cererebrospinal fluid (CSF) leak. RESULTS: CONCLUSION:
Aprepitant may serve as a useful preoperative treatment to reduce PONV in patients undergoing TSA. Further studies are needed to evaluate its impact in other arenas of endoscopic skull base surgery.
|
Authors | Daniel J Lee, Jennifer E Douglas, Jeremy Chang, Jadyn Wilensky, Christina Jackson, John Y K Lee, Michael Sean Grady, Daniel Yoshor, Michael A Kohanski, James N Palmer, Joshua H Atkins, Nithin D Adappa |
Journal | International forum of allergy & rhinology
(Int Forum Allergy Rhinol)
Vol. 13
Issue 12
Pg. 2180-2186
(Dec 2023)
ISSN: 2042-6984 [Electronic] United States |
PMID | 37302141
(Publication Type: Journal Article)
|
Copyright | © 2023 ARS-AAOA, LLC. |
Chemical References |
- Aprepitant
- Antiemetics
- Morpholines
|
Topics |
- Humans
- Aprepitant
(therapeutic use)
- Postoperative Nausea and Vomiting
(epidemiology, prevention & control, chemically induced)
- Antiemetics
(therapeutic use)
- Retrospective Studies
- Morpholines
(therapeutic use)
- Pituitary Diseases
|